Linda S. Birnbaum
Linda S. Birnbaum, Ph.D., became the Director of the National Institute of Environmental Health Sciences (NIEHS), one of the National Institutes of Health (NIH), and the National Toxicology Program (NTP) on January 18, 2009. In these roles Birnbaum oversees federal funding for biomedical research to discover how the environment influences human health and disease. Several advisory boards and councils provide Birnbaum and NIEHS/ NTP staff with input to accomplish this large task. Birnbaum is the first toxicologist and the first woman to lead the NIEHS/NTP. She has spent most of her career as a federal scientist. Birnbaum has received numerous awards and recognitions, including being elected to the Institute of Medicine of the National Academies, in October 2010, one of the highest honors in the fields of medicine and health. Birnbaum’s own research and many of her publications focus on the pharmacokinetic behavior of environmental chemicals; mechanisms of actions of toxicants, including endocrine disruption; and linking of real-world exposures to health effects. Birnbaum also finds time to mentor the next generation of environmental health scientists. For example, she serves as an adjunct professor in the Gillings School of Global Public Health, the Curriculum in Toxicology, and the Department of Environmental Sciences and Engineering at the University of North Carolina at Chapel Hill, as well as in the Integrated Toxicology Program at Duke University. A native of New Jersey, Dr. Birnbaum received her M.S. and Ph.D. in microbiology from the University of Illinois at Urbana-Champaign.
Dr. Kemper has been active in the DMPK/bioanalytical community since starting as a technician at Sterling Winthrop Research Institute in 1972. He obtained a B.Sc. in Chemistry from Rensselaer Polytechnic Institute in 1979 and a Ph.D. in Pharmacology from the University of Louisville Medical Center in 1983. He has held technical, managerial, and/or business development positions with Wyeth, RWJ PRI, Phoenix International, LCResources, and Taylor Technology/PharmaNet. Since 2010, he has been a private DMPK/bioanalytical consultant with his own firm, Pharma Navigators, LLC. He is best known for his activities with the Delaware Valley Drug Metabolism Discussion Group (DVDMDG), being on the steering committee in various positions since 1989. He also helped create the New England and RTP DMDGs and is on the steering committee of the AAPS Bioanalytical Focus Group. A frequent attendee of the Gordon Conference on Drug Metabolism, he has twice served as session chair. His CV and activities can be found on his website at www.pharmanavigatorsllc.com.
Paul B. Watkins
Dr. Paul B. Watkins is director of the Hamner-University of North Carolina Institute for Drug Safety Sciences. He is also Professor of Medicine, Pharmacy and Public Health at the University of North Carolina, Chapel Hill. Dr. Watkins is a trained clinical hepatologist and also an accomplished basic and translational investigator in the fields of drug metabolism and hepatotoxicity. He serves as the chair of both the Steering and Genetics Committees for the U.S. Drug-Induced Liver Injury Network (DILIN) (U01DK065201). He is one of the most frequently cited authors in the field of pharmacology according to www.ISIhighlycited.com. He is the recipient of numerous honors and awards including the Therapeutic Frontiers Award from the American College of Pharmacy election to the Association of American Physicians (AAP), the 2013 Agilent Therapeutic Frontiers Award, and 2015 Rawls-Palmer Award for Progress in Medicine from the American Society for Clinical Pharmacology and Therapeutics.
Gerald T. Miwa
Gerald Miwa is a consultant in the field of drug metabolism and pharmacokinetics and Adjunct Professor in the School of Pharmacy at the University of North Carolina. Previously, he was Vice President of Drug Metabolism and Pharmacokinetics (DMPK) at Millennium Pharmaceuticals in Cambridge, MA where he was responsible for ensuring that drug development candidates had adequate exposure to be effective in patients, minimizing drug-drug interactions, and anticipating toxicities arising from drug metabolites. During his career, Dr. Miwa directly contributed to the pharmaceutical development and registration of a number of drugs including: Ivermectins, Zofran, Ultiva, Zocor, Sustiva and Velcade. Dr. Miwa also led numerous research programs to develop new methods for evaluating the metabolism and pharmacokinetics of drugs and the biochemical basis for their toxicities. He is currently a member of the Executive Committee of the RTP Drug Metabolism Discussion Group and was past chairman of the Drug Metabolism Steering Committee for the Pharmaceutical Research and Manufacturers Association (PhRMA) and chairman of the Gordon Conference on Drug Metabolism. He is a member of multiple societies related to DMPK and toxicology, a Fellow of the American Association for the Advancement of Science and author of approximately 100 publications and book chapters in the DMPK field. Dr. Miwa completed his undergraduate degree in Chemistry at the University of California, San Diego, his Ph.D. in Pharmacology from the University of California, Los Angeles, and a postdoctoral fellowship at Hoffmann La Roche. Dr. Miwa was the head of DMPK at Millennium, DuPont, and Glaxo Pharmaceutical companies and a research scientist at Merck and Hoffmann La Roche companies. He currently resides in Chapel Hill, NC.
Danielle A. Mzyk
Danielle A. Mzyk is a current graduate student at North Carolina State University College of Veterinary Medicine where she is enrolled in a dual degree program, currently pursuing her Doctorate in Veterinary Medicine (DVM) and Ph.D. in Veterinary pharmacology. She has conducted research at the federal and academic levels, working with the Food and Drug Administration Center for Veterinary Medicine in Maryland and NC State University's Food Animal Residue Avoidance Databank. Her research interest areas include pharmacology of neonatal calves, food animal residue avoidance in meat and milk and ruminant internal medicine. Her academic and extracurricular achievements have earned her numerous awards including being selected by George H. Bush as a National Point of Light recipient. She is actively involved as a member of the American Association of Bovine Practitioners, American Association of Veterinary Pharmacologists and the Dairy Calf and Heifer Association. She currently serves on the RTP Drug metabolism executive committee as a student representative and also serves as the webmaster.
Jason R. Slizgi
Jason is currently a Ph.D. candidate on the UNC Eshelman School of Pharmacy. Prior to UNC, he obtained his B.S. in Pharmacology from the University of California, Santa Barbara and worked at Allergan, Inc. for two years in the Department of Pharmacokinetics and Drug Disposition. His current research focuses on the effect of liver disease on pharmacokinetics and hepatobiliary disposition under the auspices of Kim L.R. Brouwer. (https://www.linkedin.com/in/jasonslizgi)
Brante P. Sampey
Dr. Brante P. Sampey is the Associate Director of Safety Assessment for Roivant Sciences, Inc., leading nonclinical toxicology and safety pharmacology efforts to provide IND- and NDA-enabling data in support of drug development across a broad spectrum of therapeutic areas. Prior to joining Roivant Sciences, Dr. Sampey was a Sr. Study Director at Metabolon Inc. overseeing global metabolomics studies with clients from academia, government and industry; including the top 10 Pharma companies worldwide. He serves as the Chair of the Executive Committee for the RTP-DMDG (2015-2017) and has been an RTP-DMDG member for several years prior to accepting the position of Chair. Dr. Sampey received his B.S. in Biology from Virginia Tech, a Ph.D. in Toxicology from the University of Colorado Health Sciences Center (Denver) and a postdoctoral fellowship at the University of North Carolina, Chapel Hill, focusing on the overlapping fields of oncology, obesity and nutrition (Lineberger Cancer Center, Department of Nutrition and Department of Pathology & Laboratory Medicine).